Nan Fung
Life Sciences

Focused on innovation and growth in Life Sciences

OVERVIEW

A global Investor in Life Sciences

Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.

Nan Fung Life Sciences

Global Life Sciences Investment Platform

Pivotal Life Sciences >

Global Life Sciences Asset Management Platform

Pivotal bioVenture Partners (US)

Global Life Sciences VC Investor
(excluding Asia)

Pivotal bioVenture Partners (China)

Life Sciences VC Investor
Based in China

Pivotal CNS >

Global CNS Venture Capital Investor

Pivotal Growth >

Global Life Sciences Growth
Stage Investor

Public Investment >

Life Sciences Public
Investor

NFLS Platform Companies >

Building Life Sciences Companies

Fund & Co
Investments >

Investing in Life Sciences Funds

Careers

We have an important job to do. Find your role.

LATEST news

HotSpot gets hotter with $100M raise to push toward clinic

HotSpot Therapeutics, the allostery-focused biotech that works on what it calls “natural hotspots” — hence the name — is getting a bit hotter in its valuation from investors. And to that end they’ve raised $100 million.

The four-year-old AI computational biotech started by two former Nimbus execs announced this morning that it closed its Series C round right at the line of a 9-figure investment, courtesy of some big investors.

The cash won’t stop for Exscientia as it makes a $300M+ Nasdaq debut

Thursday, too, saw Exscientia raise more than just the IPO. In conjunction with the pricing, the Oxford, UK-based biotech got another $160 million in private placements from SoftBank and the Bill and Melinda Gates Foundation. With the debut, details about the big IPO winners are coming into focus. The biggest shareholder is now SoftBank, which will get a 16.3% stake after the offering. CEO Andrew Hopkins is second on the list with 15.8% of shares.